Nanjing Leads Biolabs Co., Ltd. (HKG:9887)

Hong Kong · Delayed Price · Currency is HKD

76.10

+5.65 (8.02%)

Aug 20, 2026, 4:09 PM HKT

3.61% (1Y)

Market Cap	15.14B +1.3%
Revenue (ttm)	197.25M
Net Income	-235.27M
EPS	-1.35
Shares Out	198.89M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,358,911
Open	74.05
Previous Close	70.45
Day's Range	70.20 - 77.65
52-Week Range	44.72 - 97.50
Beta	n/a
Analysts	Buy
Price Target	99.97 (+31.37%)
Earnings Date	Aug 31, 2026

About Nanjing Leads Biolabs

Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialization of novel antibody drugs worldwide. It develops therapies in oncology, autoimmune, and other severe diseases. The company’s lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma; LBL-007, a novel anti-LAG-3 antibody designed to restore T-cell activity; LBL-034, a novel GPRC5D-targeting T-cell engager for anti-tumor activity. In addition, it develops LeadsBody platform,... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2012

Employees 244

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 9887

Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

Analyst Summary

According to 4 analysts, the average rating for 9887 stock is "Buy." The 12-month stock price target is $99.97, which is an increase of 31.37% from the latest price.

Price Target

$99.97

(31.37% upside)

Analyst Consensus: Buy

Stock Forecasts